Incyte (INCY) Receivables (2010 - 2026)
Incyte (INCY) posted Receivables of $1.1 billion for Q1 2026, up 2.64% on a QoQ basis from $1.0 billion in Q4 2025, and up 27.74% year-over-year from $823.1 million in Q1 2025.
Incyte (INCY) Receivables (2010 - 2026) Analysis & Trends
Incyte's Receivables history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- Quarterly Receivables rose 27.74% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 27.74% YoY) and the FY2025 annual result came in at $1.0 billion, up 20.07% from the prior year.
- Receivables was $1.1 billion for Q1 2026 at Incyte, up from $1.0 billion in the prior quarter.
- Across five years, Receivables topped out at $1.1 billion in Q1 2026 and bottomed at $562.3 million in Q1 2022.
- A 5-year average of $759.1 million and a median of $743.6 million in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables soared 55.87% — and 2023, when it fell 6.59%.
- Incyte's Receivables stood at $644.9 million in 2022, then increased by 15.3% to $743.6 million in 2023, then advanced by 14.74% to $853.2 million in 2024, then rose by 20.07% to $1.0 billion in 2025, then gained by 2.64% to $1.1 billion in 2026.
- Business Quant data shows INCY's Receivables at $1.1 billion in Q1 2026, $1.0 billion in Q4 2025, and $895.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 4.97 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 938.02 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | 1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 895.89 Mn |
| Jun 30, 2025 | 842.89 Mn |
| Mar 31, 2025 | 823.13 Mn |
| Dec 31, 2024 | 853.15 Mn |
| Sep 30, 2024 | 758.45 Mn |
| Jun 30, 2024 | 739.05 Mn |
| Mar 31, 2024 | 745.53 Mn |
| Dec 31, 2023 | 743.56 Mn |
| Sep 30, 2023 | 657.26 Mn |
| Jun 30, 2023 | 637.99 Mn |
| Mar 31, 2023 | 623.79 Mn |
| Dec 31, 2022 | 644.88 Mn |
| Sep 30, 2022 | 618.19 Mn |
| Jun 30, 2022 | 682.97 Mn |
| Mar 31, 2022 | 562.34 Mn |
| Dec 31, 2021 | 616.30 Mn |
| Sep 30, 2021 | 516.69 Mn |
| Jun 30, 2021 | 438.17 Mn |